OXFORD, UK, September 4th, 2015 PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in...

OXFORD, UK, June 30th, 2015 PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular...

PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection…

Oxford, UK. March 4th 2015. Following another year of successful deal making, PharmaVentures is pleased to announce the appointment of Graham Combe who has joined its Business Development team. Graham has over 18 years’ experience...

OXFORD, England, February 11th 2015. PharmaVentures is pleased to announce that it is to increase its life science presence in North America by establishing a new base in Boston, MA. Starting this month Dr Adrian Dawkes, VP, will be dividing his time between the USA...

OXFORD, UK, January 27th, 2015. PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015. The University...

Pharma licensing agreement.
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally. 

OXFORD, UK, October 1st, 2014 PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature...

OXFORD, UK, September 24th, 2014 PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. Aki has been involved in over 18 start-up or...

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential…

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi’s R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010…

PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June…

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May,…

PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. A dynamic professional with formal education in…

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it’s successful admission onto London Stock Exchange’s AIM in April 2014.
Tiziana Life Sciences, is a London…

PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. These options could include reusing part of the site as a science or business park, thereby creating a legacy with the possibility…

PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space. 
Over the last 30 years, Nigel has worked…